BDNF and Dravet syndrome: We next evaluated BDNF expression in the hippocampus of adult patients with DS (13–39 years old) prior to the development of an obvious Alzheimer’s neuropathology to obtain insights into the possible translational applicability of a BDNF-mimetic strategy as a treatment for cognitive impairment.